FSD Pharma Appoints Charles Pollack Jr. MD, FACEP as Chairman of the Scientific Advisory Board

April 4, 2019 Off By BusinessWire

TORONTO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/FSDDF?src=hash” target=”_blank”gt;#FSDDFlt;/agt;–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the
“Company”), announced today the appointment of Charles V. Pollack, Jr.,
M.A., M.D., FACEP, FAAEM, FAHA, FACC, FESC, FCPP, as Chairman of its
Scientific Advisory Board (“SAB”). In this capacity Dr. Pollack will
serve as a strategic guide and resource to the Company as it develops
disruptive, science-based, cannabinoid therapeutics.

“We are very happy to have Dr. Pollack join FSD Pharma as the Chairman
of our SAB. His expertise and knowledge from the Lambert Center for the
Study of Medicinal Cannabis and Hemp, an organization he founded at the
Thomas Jefferson University in Philadelphia, will be very valuable in
shaping the biopharmaceutical strategic direction of the Company. We
look forward to gaining counsel from Dr. Pollack on the assessment of
various scientific and clinical opportunities as well as the development
of our pipeline. FSD Pharma plans to further expand our SAB to include
renowned key opinion leaders who will play a key role in our Company’s
scientific and clinical development programs,” said Dr. Raza Bokhari,
Executive Co-Chairman & Interim CEO. “On behalf of the Company, I would
also like to take this opportunity to thank Dr. Zohar Koren, our
outgoing SAB chairman for his contributions and wish him all the best in
his future endeavors,” he continued.

Dr. Charles Pollack is an international leader in emergency medicine and
has been active in teaching and clinical research. He is the only
physician to have received the American College of Emergency Physicians’
highest national awards in both teaching and research; he also received
the national teaching award from the Council of Emergency Medicine
Residency Directors. He is the only US emergency physician to be elected
a Fellow of the European Society of Cardiology. His primary emergency
care research interests are in the management of thrombosis, reversal of
anticoagulation, infectious disease emergencies, and treatment of pain.

Dr. Pollack founded The Lambert Center for the Study of Medicinal
Cannabis and Hemp at Thomas Jefferson University, in Philadelphia,
Pennsylvania, in 2016. The Center is the only comprehensive academic
resource for education, research, and practice around the use of
medicinal cannabinoids to be housed in a US university. He is also an
Editorial Board member of the journal Cannabis and Cannabinoid
Research.

From 2015-2019, Dr. Pollack served in multiple roles at Jefferson:
Associate Provost for Innovation in Education; Director, Jefferson
Institute of Emerging Health Professions; Associate Dean for CME and
Strategic Partner Alliances; and, Professor and Senior Advisor for
Interdisciplinary Research and Clinical Trials, Department of Emergency
Medicine.

Dr. Pollack graduated summa cum laude from Emory University in 1980 with
bachelor’s degrees in history and chemistry and with a master’s degree
in the history of science and medicine. He was elected to Phi Beta
Kappa. Dr. Pollack earned his medical degree from Tulane University
School of Medicine and is a member of Alpha Omega Alpha.

Dr. Pollack has written more than 500 original research articles,
chapters, and abstracts, and serves on the editorial boards of several
journals and on the steering committees of multiple national and
international studies. He is the principal investigator on multiple
ongoing trials and studies. He is also a strong advocate for
entrepreneurism and innovation in healthcare. He is a founding Board
member of the Hospital Quality Foundation, a non-for-profit education
and research organization dedicated to improvement in the quality of
care provided to patients in the hospital and at transition back to the
outpatient setting.

“I am pleased to chair the Scientific Advisory Board and work with the
FSD Pharma team to advance the Company’s strategy in cannabinoid
therapeutic programs. FSD Pharma has an opportunity to explore a unique
and exciting approach to a new class of compounds based on cannabinoid
science, which will bring new therapies to indications of high unmet
medical need. I am excited to support and guide the team as they work to
bring these innovative therapies to the market,” commented Dr. Pollack.

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor
grown, pharmaceutical grade cannabis and on the research and development
of novel cannabinoid-based treatments for several central nervous system
disorders, including chronic pain, fibromyalgia and irritable bowel
syndrome. The Company has 25,000 square feet available for production at
its Ontario facility with an additional 220,000 square feet currently in
development (with an estimated cost of $250 per square foot to be
completed in 2019).

FSD facilities sit on 70 acres of land with 40 acres primed for
development and an expansion capability of up to 3,896,000 square feet.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017. FV Pharma’s vision is to transform its
current headquarters in a Kraft plant in Cobourg, Ontario into the
largest hydroponic indoor grow facility in the world. FV Pharma intends
to cover all aspects of this exciting new industry, including
cultivation, legal, processing, manufacturing, extracts and research and
development.

Forward-Looking Information

Neither the CSE nor its Market Regulator (as that term is defined in the
policies of the CSE) accepts responsibility for the adequacy or accuracy
of this release.

Certain statements contained in this press release constitute
forward-looking information. These statements relate to future events or
future performance. The use of any of the words “could”, “intend”,
“expect”, “believe”, “will”, “projected”, “estimated” and similar
expressions and statements relating to matters that are not historical
facts are intended to identify forward-looking information and are based
on FSD Pharma’s current belief or assumptions as to the outcome and
timing of such future events. Actual future results may differ
materially. Actual results and developments may differ materially from
those contemplated by these. The forward-looking information contained
in this press release is made as of the date hereof, and FSD Pharma is
not obligated to update or revise any forward-looking information,
whether as a result of new information, future events or otherwise,
except as required by applicable securities laws. Because of the risks,
uncertainties and assumptions contained herein, investors should not
place undue reliance on forward looking-information. The foregoing
statements expressly qualify any forward-looking information contained
herein.